Basal cell carcinoma: Pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management

Yale Journal of Biology and Medicine

Volumn 88, Issue 2, 2015, Pages 167-179

  Marzuka, Alexander G ^a,b   Book, Samuel E ^a  

^a Wake Forest U   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal cell carcinoma; BCC; ED C; Electrodesiccation and curettage; Mohs surgery; Surgical excision

Indexed keywords

FLUOROURACIL; IMIQUIMOD; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI2; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RADIOTHERAPY; CLINICAL FEATURE; CRYOSURGERY; DRUG EFFECT; EPILUMINESCENCE MICROSCOPY; EXCISION; GENE LOCUS; HISTOPATHOLOGY; HUMAN; NONHUMAN; PATHOGENESIS; POINT MUTATION; PUNCH BIOPSY; RADIATION EXPOSURE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; CARCINOMA, BASAL CELL; CASE MANAGEMENT; CHEMOSURGERY; DEBRIDEMENT; ENVIRONMENTAL EXPOSURE; MULTIMODALITY CANCER THERAPY; ORGANIZATION AND MANAGEMENT; PREVALENCE; PROCEDURES; RISK FACTOR; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA; SUNLIGHT;

ERINACEIDAE;

ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CASE MANAGEMENT; COMBINED MODALITY THERAPY; DEBRIDEMENT; ENVIRONMENTAL EXPOSURE; HUMANS; MOHS SURGERY; PREVALENCE; RISK FACTORS; SKIN NEOPLASMS; SUNLIGHT;

EID: 84930164917     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithe-lioma, jaw cysts and bifid rib. A syndrome. N Engl J Med. 1960;262:908-12.
2. Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992;69(1):111-7.
3. Farndon PA, Del Mastro RG, Evans DG, Kilpatrick Mw. Location of gene for Gorlin syndrome. Lancet. 1992;339(8793):581-2.
4. Reis A, Kuster W, Linss G, Gebel E, Hamm H, Fuhrmann W, et al. Localisation of gene for the naevoid basal-cell carcinoma syndrome. Lancet. 1992;339(8793):617.
5. Gailani MR, Leffell DJ, Ziegler A, Gross EG, Brash DE, Bale AE. Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. J Natl Cancer inst. 1996;88(6):349-54.
6. Hahn H, wicking C, Zaphiropoulous PG, Gailani MR, Shan-ley S, Chidambaram A, et al. Mutations of the human ho-molog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841-51.
7. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272(5268):1668-71.
8. Stone DM, Hynes M, Armanini M, Swanson TA, Gu Q, Johnson RL, et al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature. 1996;384(6605):129-34.
9. Fan H, Oro AE, Scott MP, Khavari PA. induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat Med. 1997;3(7):788-92.
10. Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr., Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 1997;276(5313):817-21.
11. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90-2.
12. Grachtchouk M, Mo R, Yu S, Zhang X, Sasaki H, Hui CC, et al. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet. 2000;24(3):216-7.
13. Nilsson M, Unden AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, et al. induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLi-1. Proc Natl Acad Sci USA. 2000;97(7):3438-43.
14. Hutchin ME, Kariapper MS, Grachtchouk M, wang A, wei L, Cummings D, et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005;19(2):214-23.
15. O’Toole EA, Ponten F, Lundeberg J, Asplund A. Principles of Tumor Biology and Pathogenesis of BCCs and SCCs. in: Bolognia JL, Jorizzo JL, Schaffer J v, editors. Dermatology. 3rd edition. Saunders; 2012. p. 1759-72.
16. Ponten F, Berg C, Ahmadian A, Ren ZP, Nister M, Lunde-berg J, et al. Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene. 1997;15(9):1059-67.
17. Youssef KK, van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, et al. identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010;12(3):299-305.
18. Grachtchouk M, Pero J, Yang SH, Ermilov AN, Michael LE, wang A, et al. Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J Clin invest. 2011;121(5):1768-81.
19. wang GY, wang J, Mancianti ML, Epstein EH Jr. Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer Cell. 2011;19(1):114-24.
20. Seykora JT, Cotsarelis G. Keratin 15-positive stem cells give rise to basal cell carcinomas in irradiated Ptch1(+/-) mice. Cancer Cell. 2011;19(1):5-6.
21. Cancer Facts & Figures 2010. American Cancer Society [internet]. Available from: http://www.cancer.org/research/can-cerfactsstatistics/cancerfactsfigures2010/index.
22. Rogers HW, weinstock MA, Harris AR, Hinckley MR, Feld-man SR, Fleischer AB, et al. incidence estimate of non-melanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283-7.
23. Rigel DS, Friedman RJ, Kopf AW. Lifetime risk for development of skin cancer in the U.S. population: current estimate is now 1 in 5. J Am Acad Dermatol. 1996;35(6):1012-3.
24. Chuang TY, Popescu A, Su WP, Chute CG. Basal cell carcinoma. A population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol. 1990;22(3):413-7.
25. Reizner GT, Chuang TY, Elpern DJ, Stone JL, Farmer ER. Basal cell carcinoma in Kauai, Hawaii: the highest documented incidence in the United States. J Am Acad Dermatol. 1993;29(2 Pt 1):184-9.
26. Christenson LJ, Borrowman TA, vachon CM, Tollefson MM, Otley CC, weaver AL, et al. incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294(6):681-90.
27. Schreiber MM, Moon TE, Fox SH, Davidson J. The risk of developing subsequent nonmelanoma skin cancers. J Am Acad Dermatol. 1990;23(6 Pt 1):1114-8.
28. Karagas MR, Stukel TA, Greenberg ER, Baron JA, Mott LA, Stern RS. Risk of subsequent basal cell carcinoma and squa-mous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA. 1992;267(24):3305-10.
29. Marghoob A, Kopf AW, Bart RS, Sanfilippo L, Silverman MK, Lee P, et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol. 1993;28(1):22-8.
30. Marcil I, Stern RS. Risk of developing a subsequent non-melanoma skin cancer in patients with a history of non-melanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136(12):1524-30.
31. Schinstine M, Goldman GD. Risk of synchronous and metachronous second nonmelanoma skin cancer when referred for Mohs micrographic surgery. J Am Acad Derma-tol. 2001;44(3):497-9.
32. Marghoob AA, Slade J, Salopek TG, Kopf AW, Bart RS, Rigel DS. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer. 1995;75(2 Suppl):707-14.
33. Gallagher RP, Hill GB, Bajdik CD, Fincham S, Coldman AJ, McLean DI, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. i. Basal cell carcinoma. Arch Dermatol. 1995;131(2):157-63.
34. Zanetti R, Rosso S, Martinez C, Nieto A, Miranda A, Mercier M, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer. 2006;94(5):743-51.
35. Kricker A, Armstrong BK, English DR, Heenan PJ. Does intermittent sun exposure cause basal cell carcinoma? a case-control study in western Australia. int J Cancer. 1995;60(4):489-94.
36. Stern RS, PUvA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66(4):553-62.
37. wehner MR, Shive ML, Chren MM, Han J, Qureshi AA, Linos E. indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ. 2012;345:e5909.
38. Ferrucci LM, Cartmel B, Molinaro AM, Leffell DJ, Bale AE, Mayne ST. indoor tanning and risk of early-onset basal cell carcinoma. J Am Acad Dermatol. 2012;67(4):552-62.
39. Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR. Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case-control study. J invest Dermatol. 2013;133(8):1950-5.
40. Karagas MR, McDonald JA, Greenberg ER, Stukel TA, weiss JE, Baron JA, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer inst. 1996;88(24):1848-53.
41. Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect. 1998;106 Suppl 4:1047-50.
42. Boonchai W, Green A, Ng J, Dicker A, Chenevix-Trench G. Basal cell carcinoma in chronic arsenicism occurring in Queensland, Australia, after ingestion of an asthma medication. J Am Acad Dermatol. 2000;43(4):664-9.
43. Tao SS, Bolger PM. Dietary arsenic intakes in the United States: FDA Total Diet Study, September 1991-December 1996. Food Addit Contam. 1999;16(11):465-72.
44. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-91.
45. Silverberg MJ, Leyden W, warton EM, Quesenberry CP Jr., Engels EA, Asgari MM. Hiv infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer inst. 2013;105(5):350-60.
46. Cribier B, Scrivener Y, Grosshans E. Tumors arising in nevus sebaceus: A study of 596 cases. J Am Acad Dermatol. 2000;42(2 Pt 1):263-8.
47. Rosen H, Schmidt B, Lam HP, Meara JG, Labow BI. Management of nevus sebaceous and the risk of Basal cell carcinoma: an 18-year review. Pediatr Dermatol. 2009;26(6):676-81.
48. Stern RS, weinstein MC, Baker SG. Risk reduction for non-melanoma skin cancer with childhood sunscreen use. Arch Dermatol. 1986;122(5):537-45.
49. Green A, williams G, Neale R, Hart V, Leslie D, Parsons P, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354(9180):723-9.
50. Ulrich C, Jurgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161 Suppl 3:78-84.
51. Scrivener Y, Grosshans E, Cribier B. variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147(1):41-7.
52. Soyer HP, Rigel DS, wurm EM. Actinic Keratosis, Basal Cell Carcinoma and Squamous Cell Carcinoma. in: Bolog-nia JL, Jorizzo JL, Schaffer J v, editors. Dermatology. 3rd edition. Saunders; 2012. p. 1773-93.
53. Christensen SR, Leffell DJ. Cancer of the Skin. in: Devita vT, Lawrence TS, Rosenberg SA, editors. Devita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 10th edition. Lww; 2014. p. 1314-23.
54. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch Dermatol. 1997;133(5):593-6.
55. Wu PA. Epidemiology and clinical features of basal cell carcinoma 2014. UpToDate [internet]. Available from: http://www.uptodate.com/contents/epidemiology-and-clini-cal-features-of-basal-cell-carcinoma.
56. Altamura D, Menzies SW, Argenziano G, Zalaudek I, Soyer H P, Sera F, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol. 2010;62(1):67-75.
57. Zalaudek I, Kreusch J, Giacomel J, Ferrara G, Catricala C, Argenziano G. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part ii. Nonmelanocytic skin tumors. J Am Acad Dermatol. 2010;63(3):377-86; quiz 87-8.
58. Russell EB, Carrington PR, Smoller BR. Basal cell carcinoma: a comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis. J Am Acad Dermatol. 1999;41(1):69-71.
59. Haws AL, Rojano R, Tahan SR, Phung TL. Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol. 2012;66(1):106-11.
60. Roozeboom MH, Mosterd K, winnepenninckx VJ, Nele-mans PJ, Kelleners-Smeets NW. Agreement between histo-logical subtype on punch biopsy and surgical excision in primary basal cell carcinoma. J Eur Acad Dermatol venereol. 2013;27(7):894-8.
61. wolberink EA, Pasch MC, Zeiler M, van Erp PE, Gerritsen MJ. High discordance between punch biopsy and excision in establishing basal cell carcinoma subtype: analysis of 500 cases. J Eur Acad Dermatol venereol. 2013;27(8):985-9.
62. Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol. 1990;23(6 Pt 1):1118-26.
63. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006;19 Suppl 2:S127-47.
64. Aasi SZ, Leffell DJ, Lazova RZ. Atlas of Practical Mohs Histopathology. Springer; 2013. 320 p.
65. Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, et al. Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw. 2010;8(8):836-64.
66. Neville JA, welch E, Leffell DJ. Management of non-melanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007;4(8):462-9.
67. Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol. 1989;15(4):424-31.
68. Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J invest Dermatol. 2013;133(5):1188-96.
69. Blixt E, Nelsen D, Stratman E. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone. Dermatol Surg. 2013;39(5):719-25.
70. Barlow JO, Zalla MJ, Kyle A, DiCaudo DJ, Lim KK, Yian-nias JA. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol. 2006;54(6):1039-45.
71. wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123(3):340-4.
72. Gulleth Y, Goldberg N, Silverman RP, Gastman BR. what is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg. 2010;126(4):1222-31.
73. Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol. 1992;18(6):471-6.
74. Kimyai-Asadi A, Alam M, Goldberg LH, Peterson SR, Sila-punt S, Jih MH. Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol. 2005;53(3):464-8.
75. Bart RS, Schrager D, Kopf AW, Bromberg J, Dubin N. Scalpel excision of basal cell carcinomas. Arch Dermatol. 1978;114(5):739-42.
76. Dubin N, Kopf AW. Multivariate risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol. 1983;119(5):373-7.
77. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs’ mi-crographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9(12):1149-56.
78. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia ii. Outcome at 5-year follow-up. J Am Acad Dermatol. 2005;53(3):452-7.
79. Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs mi-crographic surgery. Arch Dermatol. 2002;138(8):1043-51.
80. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia iii. Per-ineural invasion. J Am Acad Dermatol. 2005;53(3):458-63.
81. Muller FM, Dawe RS, Moseley H, Fleming CJ. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatol Surg. 2009;35(9):1349-54.
82. Cook J, Zitelli JA. Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol. 1998;39(5 Pt 1):698-703.
83. Drake LA, Dinehart SM, Goltz RW, Graham GF, Hordinsky MK, Lewis Cw, et al. Guidelines of care for Mohs micro-graphic surgery. American Academy of Dermatology. J Am Acad Dermatol. 1995;33(2 Pt 1):271-8.
84. Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, et al. Ad Hoc Task Force, AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Derma-tologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531-50.
85. Silverman MK, Kopf AW, Gladstein AH, Bart RS, Grin CM, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol. 1992;18(7):549-54.
86. Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier im-iquimod. J Natl Cancer inst. 2003;95(15):1138-49.
87. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase iii, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722-33.
88. Eigentler TK, Kamin A, weide BM, Breuninger H, Caroli UM, Mohrle M, et al. A phase iii, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57(4):616-21.
89. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg. 2000;26(6):577-8; discussion 8-9.
90. Stockfleth E, Ulrich C, Hauschild A, Lischner S, Meyer T, Christophers E. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol. 2002;12(6):569-72.
91. weisberg NK, varghese M. Therapeutic response of a brother and sister with xeroderma pigmentosum to im-iquimod 5% cream. Dermatol Surg. 2002;28(6):518-23.
92. Ferreres JR, Macaya A, Jucgla A, Muniesa C, Prats C, Peyri J. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol venereol. 2006;20(7):877-8.
93. Fantini F, Greco A, Del Giovane C, Cesinaro AM, venturini M, Zane C, et al. Photodynamic therapy for basal cell carci-noma: clinical and pathological determinants of response. J Eur Acad Dermatol venereol. 2011;25(8):896-901.
94. Cosgarea R, Susan M, Crisan M, Senila S. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol venereol. 2013;27(8):980-4.
95. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol. 2012;167(4):733-56.
96. Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647-54.
97. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;10(6):1043-60.
98. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-9.
99. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Der-matol. 2014;70(1):60-9.
100. Tang JY, Mackay-wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180-8.
101. Skvara H, Kalthoff F, Meingassner JG, wolff-winiski B, Aschauer H, Kelleher JF, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J invest Dermatol. 2011;131(8):1735-44.
102. Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, et al. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res. 2011;17(10):3378-87.